Screener
Supernus Pharmaceuticals SUPN Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Inventories, net | 87,062 | 82,385 |
| Prepaid expenses and other current assets | 78,094 | 65,325 |
| Total current assets | 731,580 | 644,182 |
| Restricted cash | 1,450 | 1,450 |
| Property and equipment, net | 10,042 | 10,531 |
| Intangible assets, net | 549,712 | 569,456 |
| Goodwill | 120,668 | 124,882 |
| Deferred income tax assets, net | 30,820 | 38,351 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's restricted cash?
- Supernus Pharmaceuticals (SUPN) reported restricted cash of $1.45M in Q1 2026.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Supernus Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude